Nilandron: profile and news

Prostate Cancer Vaccine Boosts Hormone Therapy Jul 25, 2005
The patients were randomly assigned to either a recombinant prostate cancer vaccine or Nilandron (nilutamide), a second-line hormone therapy, for six months. ... - MedPage Today

Other information

Indication
Used as an add-on therapy following surgical or chemical castration due to prostate cancer

Pharmacology
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

Mechanism Of Action
Nilutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.

Drug Category
Antineoplastic Agents; ATC:L02BB02

Brand Names/Synonyms
Anandron; CHEMBANK1765; Nilandron; Nilandrone; Nilutamida [Spanish]; Nilutamide; Nilutamide [Usan:Ban:Inn]; Nilutamidum [Latin]

Dosage Forms
TABLET

Absorption
Not Available

Interactions
Interactions for Nilutamide:

In vitro, nilutamide has been shown to inhibit the activity of liver cytochrome P-450 isoenzymes and therefore, may reduce the metabolism of compounds requiring these systems.
Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, phenytoin, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level. The dosage of these drugs or others with a similar metabolism may need to be modified if they are administered concomitantly with nilutamide. For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.

Chemical IUPAC Name
5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-imidazolidine-2,4-dione

Chemical Formula
C12H10F3N3O4

Half Life
38.0-59.1 hours

Drug Type
Approved Drug

# Accession No
APRD00150

CAS Registry Number
63612-50-0